Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37571   clinical trials with a EudraCT protocol, of which   6160   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-002156-84
    Sponsor's Protocol Code Number:63623872FLZ3001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2018-04-02
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-002156-84
    A.3Full title of the trial
    A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection
    Estudio en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de pimodivir en combinación con la práctica clínica habitual en pacientes adolescentes, adultos y ancianos hospitalizados con gripe A
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    SAPPHIRE - A study to see if pimodivir in combination with standard of care treatment is useful and safe in the treatment of adolescent, adult and elderly hospitalized patients with influenza A infection.
    SAPPHIRE – Estudio para determinar si pimodivir en combinación con el tratamiento de referencia es útil y seguro para el tratamiento de pacientes adolescentes, adultos y ancianos hospitalizados con infección por el virus de la gripe A.
    A.4.1Sponsor's protocol code number63623872FLZ3001
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/135/2017
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development, LLC
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag International NV
    B.5.2Functional name of contact pointClinical Registry Group
    B.5.3 Address:
    B.5.3.1Street AddressArchimedesweg 29
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 CM
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31715242166
    B.5.5Fax number+31715242110
    B.5.6E-mailClinicalTrialsEU@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePimodivir
    D.3.2Product code JNJ-63623872-ZCD
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPimodivir
    D.3.9.1CAS number 1777721-70-6
    D.3.9.3Other descriptive nameJNJ-63623872-ZCD
    D.3.9.4EV Substance CodeSUB174944
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Influenza A Infection
    Infección por el virus de la gripe A
    E.1.1.1Medical condition in easily understood language
    Seasonal flu
    Gripe estacional
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10022002
    E.1.2Term Influenza A virus infection
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to evaluate superiority of pimodivir in combination with standard-of-care (SOC) treatment compared to placebo in combination with SOC treatment on Day 6, with respect to the clinical outcome on the hospital recovery scale.
    El objetivo principal es evaluar la superioridad de pimodivir combinado con la práctica clínica habitual en comparación con placebo combinado con la práctica clínica habitual el día 6, en cuanto al resultado clínico en la escala de recuperación hospitalaria.
    E.2.2Secondary objectives of the trial
    Compare pimodivir (Pi) in combination with SOC treatment (tmt) to placebo in combination with SOC tmt (Pi+SOC_Pl+SOC) re.:
    * Safety, tolerability
    * All-cause mortality
    * Incidence, duration of antibiotic tmt
    * No. of subjects needing extended tmt, requiring re-hospitalization, not hospitalized at Day 6
    * Time to clin response
    * Time to improvement of respiratory status
    Evaluate superiority of Pi+SOC vs.Pl+SOC with respect to:
    * Length of hospital stay, time in ICU, time on mechanical ventilation, time to return to daily activities
    * Clinical outcome on hospital recovery scale
    * Incidence of complications associated with influenza after start of study tmt
    * Time to viral negativity a. viral load over time by qRT-PCR and viral culture
    * PK of Pi; PK/PD relationships of Pi
    Investigate:
    * Acceptability (taste, swallowability) of Pi formulation in adolescents
    * Emergence of viral resistance against Pi
    * Virologic response by baseline resistance to Pi/other antivirals in SOC
    Comparar pimovidir (Pi) en combinación con (SOC) con placebo en combinación con SOC (Pi+SOC_Pl+SOC) en cuanto a:
    * Seguridad/tolerabilidad
    * Mortalidad por cualquier causa.
    * Incidencia/duración del tratamiento (Tr) antibiótico
    * N.º de sujetos que necesitan Tr ampliado, requieren rehospitalización, no hospitalizados el día 6
    * Tiempo (T) hasta :la respuesta clínica y hasta la mejora del estado respiratorio
    Evaluar la superioridad de Pi+SOC frente a Pl+SOC en cuanto a:
    * Duración del ingreso hospitalario, T en la UCI, T con ventilación mecánica, T transcurrido hasta retomar las actividades cotidianas
    * Escala de recuperación hospitalaria
    * Incidencia de complicaciones
    * T hasta la negatividad vírica y carga vírica con el paso del T mediante RCP-TRc y cultivo vírico
    * FC de Pi; relaciones FC/FD de Pi
    Investigar:
    * Aceptabilidad en adolescentes
    * Aparición de resistencia vírica contra Pi
    * Respuesta virológica según la resistencia inicial a Pi/otros antivíricos en SOC
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Taste and Swallowability in adolescents (integrated part of the protocol)
    Sabor y facilidad para ser tragado en adolescentes (parte integrada en el protocolo)
    E.3Principal inclusion criteria
    • Male or female, 13 to 85 years of age, inclusive. Note: Adolescent subjects (13-17 years) will be enrolled in selected countries and study sites consistent with local regulations.
    • Tested positive for influenza A infection after the onset of symptoms using a polymerase chain reaction (PCR)-based molecular diagnostic assay.
    • Requires hospitalization to treat influenza infection and/or to treat complications of influenza infection (eg, radiological signs of lower respiratory tract disease, septic shock, central nervous system [CNS] involvement, myositis, rhabdomyolysis, acute exacerbation of chronic kidney disease, severe dehydration, myocarditis, pericarditis, ischemic heart disease, exacerbation of underlying chronic pulmonary disease, including asthma, chronic obstructive pulmonary disease [COPD], decompensation of previously controlled diabetes mellitus), including subjects admitted to the intensive care unit (ICU). Note: For the purpose of the protocol, subjects admitted under “observation” status with an anticipated length of stay beyond 24 hours are eligible for enrollment.
    • Enrollment and initiation of study drug treatment ≤96 hours after onset of influenza symptoms.
    • Having an SpO2 <94% on room air. Subjects with known pre influenza SpO2 <94% must have an SpO2 decline ≥3% from pre-influenza SpO2.
    • Having a screening/baseline NEWS of ≥4.

    Treatment Extension Criteria - Subjects will be given the option for treatment extension in case all of the following conditions are met:
    • The subject completed the 5-day treatment period.
    • The subject is still hospitalized.
    • Subject has an ongoing respiratory deficiency as evidenced by having an SpO2 <94% on room air, or in case of pre-existing chronic hypoxia (eg, due to COPD), the current blood oxygen saturation on room air is lower than pre-influenza infection levels by at least 2%.
    • The subject is expected to derive clinical benefit from extending the treatment period, in the opinion of the investigator.
    • The investigator agrees to extend treatment with the same SOC. If the SOC contained no influenza antiviral during the first treatment period, no new influenza antiviral can be started in the treatment extension as part of the SOC.
    • Hombres o mujeres con edades comprendidas entre los 13 y los 85 años, inclusive. Nota: Los pacientes adolescentes (13-17 años) se inscribirán en países y centros de estudio seleccionados de conformidad con las normativas locales.
    • Positivo para gripe A tras el inicio de los síntomas empleando un ensayo diagnóstico molecular basado en la reacción en cadena de la polimerasa (RCP).
    • Requiere hospitalización para tratar la gripe y/o las complicaciones de la gripe (p. ej., signos radiológicos de enfermedad de las vías respiratorias inferiores, choque septicémico, afectación del sistema nervioso central [SNC], miositis, rabdomiólisis, exacerbación aguda de enfermedad renal crónica, deshidratación grave, miocarditis, pericarditis, cardiopatía isquémica, exacerbación de enfermedad pulmonar subyacente, incluyendo asma, enfermedad pulmonar obstructiva crónica [EPOC], descompensación de diabetes mellitus anteriormente controlada), incluidos los pacientes ingresados en la unidad de cuidados intensivos (UCI). Nota: Para los fines del protocolo, los pacientes ingresados en estado de “observación” con una duración anticipada del ingreso superior a 24 horas son aptos para su inscripción.
    • Inscripción e inicio del tratamiento con el fármaco del estudio ≤96 horas después del inicio de los síntomas de gripe.
    • Presentar una SpO2 <94 % con aire ambiental. Los pacientes con una SpO2 conocida antes de la gripe de <94 % deberán presentar un descenso en la SpO2 de ≥3 % con respecto a la SpO2 anterior a la gripe.
    • Presentar una puntuación NEWS ≥4 en la selección/inicio
    Criterios de prolongación del tratamiento
    Los pacientes tendrán la opción de prolongar el tratamiento en caso de que se cumplan todas las condiciones siguientes:
    • El paciente ha completado el periodo de tratamiento de 5 días.
    • El paciente sigue ingresado.
    • El paciente presenta una deficiencia respiratoria demostrada por una SpO2 <94 % con aire del ambiente o, en caso de hipoxia crónica preexistente (p. ej., debido a EPOC), la saturación de oxígeno en sangre actual con aire del ambiente es inferior a los niveles anteriores a la gripe en al menos un 2 %.
    • Se espera que el paciente obtenga beneficio clínico de la prolongación del periodo de tratamiento, a juicio del investigador.
    • El investigador accede a prolongar el tratamiento con la misma práctica clínica habitual. Si la práctica clínica habitual no contenía antivíricos contra la gripe durante el primer periodo de tratamiento, no podrá iniciarse un antivírico contra la gripe nuevo en la prolongación del tratamiento como parte de la práctica clínica habitual.
    E.4Principal exclusion criteria
    • Received more than 3 doses of influenza antiviral medication (eg, oseltamivir [OST] or zanamivir), or any dose of ribavirin within 2 weeks, prior to first study drug intake. Received intravenous (IV) peramivir more than one day prior to screening.
    • Unwilling to undergo regular nasal mid-turbinate (MT) swabs or has any physical abnormality which limits the ability to collect regular nasal MT specimens.
    • Unstable angina pectoris or myocardial infarction within 30 days prior to screening (inclusive).
    • Presence of clinically significant heart arrhythmias, uncontrolled, unstable atrial arrhythmia, or sustained ventricular arrhythmia, or risk factors for Torsade de Pointes syndrome.
    • Chronic hepatitis C infection undergoing antiviral therapy.
    • Severely immunocompromised in the opinion of the investigator (eg, cluster of differentiation 4+ [CD4+] count <200 cells/mm3, absolute neutrophil count <750/mm3, first course of chemotherapy completed within 2 weeks prior to screening, history of stem cell transplant within 1 year prior to screening, any history of a lung transplant).
    • Haber recibido más de 3 dosis de medicación antivírica contra la gripe (p. ej., oseltamivir [OST] o zanamivir), o cualquier dosis de ribavirina en las 2 semanas anteriores a la primera dosis del fármaco del estudio. Haber recibido peramivir intravenoso (IV) más de un día antes de la selección.
    • No estar dispuesto a someterse a las recogidas regulares de muestras con hisopo del cornete nasal medio o presentar una anomalía física que limite la capacidad para recoger muestras regulares del cornete nasal medio.
    • Angina de pecho inestable o infarto de miocardio en los 30 días anteriores a la selección (inclusive).
    • Presencia de arritmias cardíacas, arritmia auricular inestable no controlada o arritmia ventricular sostenida que sean clínicamente significativas, o factores de riesgo de síndrome de Torsade de Pointes.
    • Infección crónica por hepatitis C con tratamiento antivírico en curso.
    • Estar gravemente inmunocomprometido a criterio del investigador (p. ej., recuento del cúmulo de diferenciación 4+ [CD4+] <200 células/mm3, recuento absoluto de neutrófilos <750/mm3, primera tanda de quimioterapia completada en las 2 semanas anteriores a la selección, antecedentes de trasplante de células madre en el plazo de 1 año antes de la selección, antecedentes de trasplante de pulmón).
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is the hospital recovery scale as assessed on Day 6.
    El criterio de valoración principal es la escala de recuperación hospitalaria evaluada el día 6
    E.5.1.1Timepoint(s) of evaluation of this end point
    The hospital recovery scale assesses a subject’s clinical status and will be assessed as the subject’s condition on Day 6 as the primary endpoint.
    La escala de recuperación hospitalaria evalúa el estado clínico de un paciente y se evaluará como el estado del paciente el día 6 como criterio de valoración principal.
    E.5.2Secondary end point(s)
    1. Safety and tolerability based on assessment of AEs, clinical laboratory assessments, 12-lead electrocardiograms (ECGs), vital signs, and peripheral capillary oxygen saturation.
    2. Length of hospital stay.
    3. Length of time in the ICU.
    4. Length of time on mechanical ventilation.
    5. The hospital recovery scale as assessed each separate day from Days 4 to 14 (excluding the primary time point).
    6. Time to return to daily activities.
    7. Incidence of complications associated with influenza after the start of study treatment.
    8. All-cause mortality.
    9. Incidence and duration of antibiotic treatment.
    10. The number (proportion) of subjects needing extended treatment.
    11. The number (proportion) of subjects requiring re-hospitalization.
    12. The number (proportion) of subjects not hospitalized at Day 6.
    13. Time to clinical response.
    14. Time to respiratory response.
    15. PK parameters of pimodivir (ie, plasma concentration just prior to the beginning or at the end of a dosing interval [Ctrough], Cmax, tmax, and AUC12h), as determined by population PK analysis.
    16. PK/pharmacodynamic (PD) analyses.
    17. The acceptability of the pimodivir formulation in adolescents, as measured by a taste and swallowability questionnaire.
    18. Time to viral negativity by qRT-PCR and viral culture.
    19. Viral load over time by qRT-PCR and viral culture.
    20. The emergence of viral resistance against pimodivir detected by genotyping and/or phenotyping.
    21. Virologic response by baseline viral resistance to pimodivir/other antivirals in the SOC.
    1.Seguridad y tolerabilidad según la evaluación de AA, evaluaciones analíticas, electrocardiogramas (ECG) de 12 derivaciones, constantes vitales y saturación de oxígeno en los capilares periféricos.
    2.Duración del ingreso hospitalario
    3.Duración de la estancia en la UCI.
    4.Duración del tiempo con ventilación mecánica.
    5.Escala de recuperación hospitalaria evaluada cada uno de los días desde el día 4 al 14 (excluyendo el punto temporal primario).
    6.Tiempo transcurrido hasta retomar las actividades cotidianas.
    7.Incidencia de complicaciones asociadas con la gripe después del inicio del tratamiento del estudio.
    8.Mortalidad por cualquier causa.
    9.Incidencia y duración del tratamiento antibiótico.
    10.Número (proporción) de pacientes que necesitan tratamiento prolongado.
    11Número (proporción) de pacientes que necesitan repetir la hospitalización.
    12.Número (proporción) de pacientes no hospitalizados el día 6.
    13.Tiempo hasta la respuesta clínica.
    14.Tiempo hasta la respuesta respiratoria.
    15.Parámetro de FC de pimodivir (es decir, concentración plasmática justo antes del inicio o al final del intervalo posológico [Cvalle], Cmáx, tmáx y ABC12h), según se determine mediante un análisis de FC poblacional.
    16.Análisis de FC/farmacodinámica (FD).
    17.Aceptabilidad de la formulación de pimodivir en adolescentes, según se determine mediante un cuestionario de sabor y facilidad para ser tragado.
    18.Tiempo hasta la negatividad vírica mediante RCP-cTR y cultivo vírico.
    19.Carga vírica con el paso del tiempo mediante RCP-cTR y cultivo vírico.
    20.Aparición de resistencia vírica contra pimodivir detectada mediante genotipificación y/o fenotipificación.
    21.Respuesta virológica según la resistencia inicial a pimodivir/otros antivíricos en la práctica clínica habitual.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1.-4., 6.-9. Day 33
    5. Day 14
    10.-16. Final analysis
    17. Day 5
    18.-20 Day19
    21. Day 0/1
    1.-4., 6.-9. Dia 33
    5. Dia 14
    10.-16. Análisis Final
    17. Dia 5
    18.-20 Dia 19
    21. Dia 0/1
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    - Acceptability of pimodivir formulation in adolescents
    - Emergence of viral resistance against pimodivir
    - Virologic response to pimodivir/other antivirals in the SOC
    - Aceptabilidad de la formulación de pimovidir en adolescentes
    - Aparición de resistencia vírica contra pimovidir
    - Respuesta virológica según la resistencia inicial a pimodivir/otros antivíricos en la práctica clínica habitual
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Diseño del tratamiento complementario de la práctica clínica habitual (elección del investigador: tr
    Add-on design to SoC (investigator's choice: antiviral therapy and/or supportive care)
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA105
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Belgium
    Brazil
    Bulgaria
    Chile
    Czech Republic
    France
    Germany
    Hungary
    India
    Israel
    Italy
    Korea, Republic of
    Latvia
    Lithuania
    Malaysia
    Mexico
    Netherlands
    New Zealand
    Peru
    Poland
    Romania
    Russian Federation
    Singapore
    Slovakia
    South Africa
    Spain
    Sweden
    Taiwan
    Thailand
    Turkey
    Ukraine
    United States
    Vietnam
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUP
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days11
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 60
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 60
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 270
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 270
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Adolescents 13 to 17 years old
    Adolescentes entre 13 y 17 años de edad
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state56
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 236
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-06-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-06-27
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA